Header cover image

Hong Kong (HSI) Biotech Industry Analysis

UpdatedJun 15, 2024
DataAggregated Company Financials
Companies48
  • 7D0.5%
  • 3M-5.5%
  • 1Y-36.9%
  • YTD-15.8%

Over the last 7 days, the Biotech industry has remained flat, although notably Innovent Biologics gained 7.0%. Unfortunately though, the industry is down 37% over the past 12 months. Earnings are forecast to grow by 36% annually.

Industry Valuation and Performance

Has the Hong Kong Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 15 Jun 2024HK$339.0bHK$49.7b-HK$19,479,313,074.0010.5x-17.4x6.8x
Mon, 13 May 2024HK$381.6bHK$49.9b-HK$19,280,058,128.7112.4x-19.8x7.6x
Wed, 10 Apr 2024HK$348.5bHK$49.3b-HK$19,515,680,148.9711x-17.9x7.1x
Fri, 08 Mar 2024HK$335.4bHK$47.2b-HK$20,389,266,599.6415.3x-16.4x7.1x
Sun, 04 Feb 2024HK$298.0bHK$46.8b-HK$20,180,773,943.0015x-14.8x6.4x
Tue, 02 Jan 2024HK$409.5bHK$47.3b-HK$20,423,453,967.0017.7x-20.1x8.7x
Thu, 30 Nov 2023HK$408.3bHK$46.5b-HK$18,752,881,282.0019x-21.8x8.8x
Sat, 28 Oct 2023HK$397.2bHK$44.9b-HK$19,035,005,211.0013.4x-20.9x8.8x
Mon, 25 Sep 2023HK$413.2bHK$44.9b-HK$18,918,406,180.0016.5x-21.8x9.2x
Wed, 23 Aug 2023HK$370.9bHK$35.9b-HK$22,907,163,046.0014.7x-16.2x10.3x
Fri, 21 Jul 2023HK$389.8bHK$35.5b-HK$23,381,657,031.0025.4x-16.7x11x
Sun, 18 Jun 2023HK$420.9bHK$35.8b-HK$23,587,907,883.0025.5x-17.8x11.8x
Tue, 16 May 2023HK$446.8bHK$36.5b-HK$24,154,441,532.0031.6x-18.5x12.2x
Thu, 13 Apr 2023HK$457.4bHK$37.0b-HK$24,166,995,434.0018.8x-18.9x12.4x
Sat, 11 Mar 2023HK$384.0bHK$32.9b-HK$36,072,787,903.0023.3x-10.6x11.7x
Mon, 06 Feb 2023HK$474.1bHK$35.0b-HK$35,372,745,817.0030.7x-13.4x13.6x
Wed, 04 Jan 2023HK$421.5bHK$34.3b-HK$34,558,058,099.0027.1x-12.2x12.3x
Fri, 02 Dec 2022HK$358.3bHK$33.3b-HK$33,534,642,762.0021.9x-10.7x10.8x
Sun, 30 Oct 2022HK$326.1bHK$31.6b-HK$32,117,634,240.0015.3x-10.2x10.3x
Tue, 27 Sep 2022HK$285.3bHK$33.7b-HK$32,905,028,932.0020.5x-8.7x8.5x
Thu, 25 Aug 2022HK$319.2bHK$33.6b-HK$41,231,286,975.0011.7x-7.7x9.5x
Sat, 23 Jul 2022HK$355.9bHK$32.8b-HK$46,264,777,795.0013.9x-7.7x10.8x
Mon, 20 Jun 2022HK$346.7bHK$33.0b-HK$46,543,563,472.0014.2x-7.4x10.5x
Wed, 18 May 2022HK$337.1bHK$33.9b-HK$45,711,035,896.0013.3x-7.4x9.9x
Fri, 15 Apr 2022HK$348.1bHK$36.4b-HK$46,232,583,949.0013.6x-7.5x9.6x
Sun, 13 Mar 2022HK$303.1bHK$34.0b-HK$31,197,209,607.0012.7x-9.7x8.9x
Tue, 08 Feb 2022HK$303.1bHK$31.1b-HK$31,825,745,693.0011.9x-9.5x9.7x
Thu, 06 Jan 2022HK$352.4bHK$31.1b-HK$31,791,809,096.0012.8x-11.1x11.3x
Sat, 04 Dec 2021HK$475.4bHK$31.0b-HK$31,771,215,941.0013.5x-15x15.3x
Mon, 01 Nov 2021HK$470.3bHK$30.8b-HK$31,564,064,070.0014.3x-14.9x15.2x
Wed, 29 Sep 2021HK$517.0bHK$30.5b-HK$31,485,203,054.0015.1x-16.4x17x
Fri, 27 Aug 2021HK$492.3bHK$30.2b-HK$32,058,827,347.3516.7x-15.4x16.3x
Sat, 03 Jul 2021HK$651.9bHK$30.2b-HK$32,058,827,347.3519.7x-20.3x21.6x
Price to Earnings Ratio

-20.3x


Total Market Cap: HK$651.9bTotal Earnings: -HK$32,058,827,347.35Total Revenue: HK$30.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Biotech Industry Price to Earnings3Y Average -14.5x202220232024
Current Industry PE
  • Investors are pessimistic on the Hong Kong Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 11.1x is higher than the industry's current PS ratio of 6.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?

HK Market-1.82%
Healthcare-0.71%
Biotech0.54%
Biotech0.54%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
1801 Innovent BiologicsHK$38.307.0%
+HK$4.1b
4.4%PS9.3x
9995 RemeGenHK$27.406.6%
+HK$914.5m
-25.5%PS11x
6855 Ascentage Pharma Group InternationalHK$23.0510.8%
+HK$640.4m
3.8%PS27.5x
2162 Keymed BiosciencesHK$35.306.8%
+HK$622.4m
-22.1%PS25.6x
2179 Jiangsu Recbio TechnologyHK$9.0514.7%
+HK$555.8m
-36.3%PS132.6x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

9995

HK$27.40

RemeGen

7D

6.6%

1Y

-25.5%

6855

HK$23.05

Ascentage Pharma Group International

7D

10.8%

1Y

3.8%

9926

HK$39.85

Akeso

7D

-2.0%

1Y

6.4%

1952

HK$20.25

Everest Medicines

7D

-2.9%

1Y

25.8%

6660

HK$7.09

AIM Vaccine

7D

2.9%

1Y

-84.9%

9966

HK$2.68

Alphamab Oncology

7D

-6.0%

1Y

-67.3%

2179

HK$9.05

Jiangsu Recbio Technology

7D

14.7%

1Y

-36.3%

2511

HK$4.10

HighTide Therapeutics

7D

-8.5%

1Y

n/a

6978

HK$3.30

Immunotech Biopharm

7D

13.8%

1Y

-30.5%